Zacks Investment Research
20 Jul 2026, 22:51 UTC · 9h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Recursion Pharmaceuticals (RXRX) is projected to report a revenue decline of 37.64% for the upcoming quarter compared to the previous year. — A significant drop in quarterly revenue typically signals weakening fundamentals and puts downward pressure on stock price.
-0.60Recursion Pharmaceuticals (RXRX) is expected to report an EPS of -$0.25, a 39.02% improvement over the same quarter last year. — While still negative, the reduction in losses suggests improving operational efficiency or cost management.
+0.30The Medical - Biomedical and Genetics industry is ranked in the top 40% of all industries by Zacks. — Broad industry strength provides a supportive tailwind for companies operating within this sector.
+0.20Continue reading
6 related stories
Top 1 mover · tap to explore
Recursion Pharmaceuticals currently holds a Zacks Rank of #3 (Hold). — A 'Hold' rating implies a neutral outlook with no strong conviction for immediate buying or selling.
+0.00Which stocks this story touches
The stock price has depreciated 8.82% over the past month and underperformed its sector, with a projected revenue decline of 37.64% for the upcoming quarter.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
3h ago
